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Abstract
Background: Schistosomiasis is a parasitic disease caused by trematodes of the genus Schistosoma. Five species of
Schistosoma are known to infect humans, out of which S. haematobium is the most prevalent, causing the chronic parasitic
disease schistosomiasis that still represents a major problem of public health in many regions of the world and especially in
tropical areas, leading to serious manifestations and mortality in developing countries. Since the 1970s, praziquantel (PZQ) is
the drug of choice for the treatment of schistosomiasis, but concerns about relying on a single drug to treat millions of
people, and the potential appearance of drug resistance, make identification of alternative schistosomiasis chemotherapies
a high priority. Alkylphospholipid analogs (APLs), together with their prototypic molecule edelfosine (EDLF), are a family of
synthetic antineoplastic compounds that show additional pharmacological actions, including antiparasitic activities against
several protozoan parasites.
Methodology/Principal Findings: We found APLs ranked edelfosine. perifosine. erucylphosphocholine. miltefosine for
their in vitro schistosomicidal activity against adult S. mansoni worms. Edelfosine accumulated mainly in the worm
tegument, and led to tegumental alterations, membrane permeabilization, motility impairment, blockade of male-female
pairing as well as induction of apoptosis-like processes in cells in the close vicinity to the tegument. Edelfosine oral
treatment also showed in vivo schistosomicidal activity and decreased significantly the egg burden in the liver, a key event
in schistosomiasis.
Conclusions/Significance: Our data show that edelfosine is the most potent APL in killing S. mansoni adult worms in vitro.
Edelfosine schistosomicidal activity seems to depend on its action on the tegumental structure, leading to tegumental
damage, membrane permeabilization and apoptosis-like cell death. Oral administration of edelfosine diminished worm and
egg burdens in S. mansoni-infected CD1 mice. Here we report that edelfosine showed promising antischistosomal
properties in vitro and in vivo.
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Introduction
Schistosomiasis is a parasitic disease caused by trematodes of the
genus Schistosoma, being a major problem of public health. The
genus Schistosoma contains 21 species, which are classified into
four groups according to the geographic distribution, morphology
of the parasite’s eggs, and the intermediate host. Five major
schistosome species are able to infect humans: S. haematobium, S.
mansoni, S. intercalatum, S. japonicum, and S. mekongi, although
human infections by S. malayensis, S. mattheei, and S. guineensis
have also been described. Schistosomiasis is acquired by contact
with freshwater contaminated with cercariae larvae, which actively
penetrate mammal skin and transform into the schistosomula
phase, migrating toward the lungs and then re-entering the venous
circulation [1]. Both male and female schistosome parasites
achieve sexual maturity in the bloodstream, then sexual repro-
duction occurs with the deposition of hundreds to thousands of
eggs per day. Deposition of Schistosome eggs in the tissues is a
stimulus to the influx of immune cells that leads to the
development of a granulomatous reaction. This immunological
reaction protects the host by neutralizing the schistosome egg
antigens and destroying eggs. However, the granulomas are the
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most important pathogenic event in schistosomiasis since the
deposition of collagen and the development of fibrosis cause the
fibro-obstructive disease. Nevertheless, paradoxically, the devel-
opment of granulomatous inflammation around parasite eggs has
an essential host-protective and facilitates the successful excretion
of the eggs from the host [2–4]. The World Health Organization
(WHO) announced in October 2001 that schistosomiasis epide-
miology should be recalculated. It is estimated more than 700
million people in 78 countries endemic for schistosomiasis are at
risk of this disease. Furthermore, 240 million people are infected
(80% in sub-Saharan Africa), 120 million have symptoms, and 20
million have severe disease, which results in approximately
280,000 deaths annually [2,5,6]. An additional report even
increases the estimate of infected people to 391–597 million [7].
Some authors report the significant impact of the morbidity caused
by schistosomiasis, as reflected in the loss of 1.53 million disability-
adjusted life years [1]. The disease is among the Neglected
Tropical Diseases catalogued by the Global Plan to combat
Neglected Tropical Diseases 2008–2015, and is considered to be
the second most socioeconomically devastating parasitic disease by
the WHO, immediately after malaria [8].
Praziquantel is the main drug for the treatment of schistosomi-
asis, since oxamniquine and metrifonate are not currently
available [9,10]. However, praziquantel does not prevent reinfec-
tion and its administration requires taking into consideration the
stage of the disease. Praziquantel is highly efficient against adult
worms, being less effective against juvenile parasites (7–35 days)
[11]. In the chronic phase, the dose of praziquantel depends on
the species involved [2,12]. The fact that schistosomiasis treatment
is limited to one single pharmaceutical presents the risk associated
with the appearance of resistances. The WHO has recognized the
necessity of identifying new compounds as alternatives to
praziquantel. In the last decade, only derivatives of artemisinin
have appeared as a complement to the therapy against schisto-
somiasis. The use of these derivatives in combination with
praziquantel can be a good strategy of control, since the
artemisinin derivatives are effective against the juvenile phases of
the parasite [9]. In addition, the activity of the artemisinin
derivatives as antiparasitic chemotherapy has been demonstrated
in numerous clinical trials [13–15]. However, the use of these
antimalarial drugs in the treatment and/or control of schistoso-
miasis might lead to the appearance of malaria resistance to these
compounds. Several experts are warning about the putative
emergence of resistance to praziquantel, due to its massive use in
schistosomiasis control campaigns, and the existence of drug
resistant parasites in laboratory isolates [16]. This makes it
necessary to find new molecules or therapeutic targets for
schistosomiasis control.
Alkylphospholipid analogs (APLs) are a class of structurally
related synthetic lipid compounds, including edelfosine, miltefo-
sine, perifosine, and erucylphosphocholine (Figure 1), that act on
cell membranes rather than on DNA [17–19]. Edelfosine (1-O-
octadecyl-2-O-methyl-rac-glycero-3-phosphocholine), considered
as the prototype APL molecule, is a promising antitumor ether
phospholipid drug [20–22], which acts by activating apoptosis
through its interaction with cell membranes [19,23–25]. In
addition to its antitumor activity, edelfosine has been shown to
exert in vitro and in vivo antiparasitic activity against different
species of Leishmania parasites [26]. Miltefosine has also been
shown to exert activity against leishmaniasis and schistosomiasis
[27,28]. Both Leishmania and Schistosoma parasites share
geographic areas in tropical and subtropical countries [29,30].
Here we have investigated the putative anti-schistosomal proper-
ties of edelfosine, as compared to other APLs, by in vitro and in
vivo approaches, using an experimental mouse model of S.
mansoni infection.
Figure 1. Chemical structures of edelfosine, miltefosine, perifosine and erucylphosphocholine.
doi:10.1371/journal.pone.0109431.g001
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Materials and Methods
Ethics statement
Animal procedures in this study complied with the Spanish (Ley
32/2007, Ley 6/2013 and Real Decreto 53/2013) and the
European Union (European Directive 2010/63/EU) regulations
on animal experimentation for the protection and humane use of
laboratory animals, and were conducted at the accredited Animal
Experimentation Facility of the University of Salamanca (Register
number: PAE/SA/001). Procedures were approved by the Ethics
Committee of the University of Salamanca (protocol approval
number 48531). The animals’ health status was monitored
throughout the experiments by a health surveillance program
according to Federation of European Laboratory Animal Science
Associations (FELASA) guidelines.
Drugs
Edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phospho-
coline) was obtained from R. Berchtold (Biochemisches Labor,
Bern, Switzerland). Miltefosine (hexadecylphosphocholine) was
from Calbiochem (Cambridge, MA). Perifosine (octadecyl-(1,1-
dimethyl-piperidinio-4-yl)-phosphate) and erucylphosphocholine
((13Z)-docos-13-en-1-yl 2-(trimethylammonio)ethyl phosphate)
were from Zentaris (Frankfurt, Germany). Stock sterile solutions
of the distinct APLs (2 mM) were prepared in RPMI-1640 culture
medium (Invitrogen, Carlsbad, CA), supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 2 mM glutamine, 100
IU/mL penicillin, and 100 mg/mL streptomycin, as previously
described [20]. Praziquantel (PZQ) was obtained as Biltricide
tablets (Bayer Vital, Leverkusen, Germany) and was dispersed in
water with 2–2.5% Cremophor A6 oil-in-water emulsifier (Sigma,
MO).
Parasite maintenance, recovery and culture
Cercariae of Schistosoma mansoni (LE strain) were maintained
routinely in Biomphalaria glabrata snails and female CD1 mice
(Charles River, Criffa S.A., Barcelona, Spain) at University of
Salamanca. Mice were maintained in polycarbonate and wire
standard cages for 10 mice with food and water ad libitum in an
environment under an alternating 12/12-h light-dark cycle at
20uC. Six-week-old females weighing 23–26 g were percutane-
ously infected with 150 S. mansoni cercariae per animal after
being restrained with a mixture of ketamine 50 mg/kg of body
weight, diazepam 5 mg/kg and atropine 1 mg/kg injected
intraperitoneally. After 7–8 weeks, mice were killed with a lethal
dose of 60 mg/kg of pentobarbital plus heparin (2 IU/mL) and
then perfused aseptically with PBS and heparin (500 IU/L) to
obtain couples, males and females from the portal and mesenteric
veins [31,32]. The worms were washed in RPMI-1640 culture
medium (Invitrogen, Carlsbad, CA), kept at pH 7.5 with 20 mM
HEPES and supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 2 mM L-glutamine, 100 IU/mL penicillin, and
100 mg/mL streptomycin, as previously described [31]. All mice
were monitored daily by the staff from Animal Experimentation
facility and after day 42 post-infection by a member of the
research group qualified in animal welfare. Animals presenting
any deterioration of the health status were killed with a lethal dose
of pentobarbital 60 mg/kg.
In vitro antischistosomal activity
Adult worms washed in RPMI-1640 were collected, counted,
and transferred to RPMI-1640 medium (supplemented with
20 mM HEPES, 100 IU/mL penicillin, 100 mg/mL streptomycin
and 2 mM L-glutamine). The worms were rinsed twice with this
medium and distributed one pair of adult worms per well in 24-
well culture plates. FBS was added to a final concentration of 10%,
and the cultures were incubated at 37uC in a 5% CO2
atmosphere. After 2 h of culture to allow for adaptation, APLs
were added to a final concentration of 1 to 80 mM (from a stock
solution of 2 mM in RPMI-1640). The effects of APLs on S.
mansoni adult worms were monitored every 24 h during 168 h for
control groups and APL treatments. A number of parameters were
evaluated to assess worm general condition, including: motility,
alterations in the tegument, mortality rate, and changes in pairing
[33]. The worms were considered dead when no movement was
detected for at least 2 min of examination [34]. Additional criteria
for viability were the MTT assay (see below), as well as pairing,
egg production, and video-imaging to record morphological
alterations and dead worms [35]. Worms were observed under a
Nikon eclipse Ti inverted research microscope (Nikon Instru-
ments, Amstelveen, The Netherlands). Video recordings were
taken using a ProgRes C3 camera and a ProgRes MAC
CapturePro software version 2.7 (JENOPTIK Optical Systems,
Jena, Germany). As controls, pairs of S. mansoni adult worms were
incubated in the presence RPMI-1640 (negative control) or were
killed by heating at 56uC or treatment with 10 mM PZQ (positive
control). All experiments were carried in quadruplicate.
Assay for parasite viability
A three-step colorimetric quantitative assay based on 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
was used to assess parasite viability [36]. The MTT assay is based
on the uptake of the tetrazolium salt by viable/living cells followed
by its reduction in the mitochondria to purple formazan, the
colored product. The amount of formazan produced is propor-
tional to the number of living cells, giving a measure of viability. In
this study, worms were distributed (one pair of adult worms per
well) in 96-well culture plates, containing 100 mL of phosphate
buffered saline (PBS) with 0.5 mg MTT/mL for 30 min at 37uC.
The solution was carefully removed and replaced with 200 mL
dimethylsulfoxide (DMSO). Worms incubated in drug-free RPMI-
1640 medium (negative control group) were allowed to stand in
DMSO at room temperature for 1 h, and absorbance was read at
550 nm using an ELISA reader (Anthos 2010; Anthos Labtec
Instruments, Wals, Austria). Heat-killed worms at 56uC and
worms treated with 10 mM PZQ were used as positive control
groups. APLs were added to a final concentration of 1 to 80 mM
(from a stock solution of 2 mM in RPMI-1640) for up to 168 h
incubation.
We studied the incorporation of propidium iodide (PI) in adult
worms to assess the differential membrane permeability to this
dye. The effect of edelfosine (1–80 mM) was analyzed following
incubation for 24 h. After washing the parasites, PI was
simultaneously added to each well of the microtiter plate to
obtain a final concentration of 2.0 mg/mL in 96-well microtiter
plates. Fluorescently labeled parasites were subsequently detected
using a BioTek Synergy 2 (BioTek Instruments, Winooski, VT)
fluorescent plate reader containing appropriate filters (485/20 nm
excitation, 645/20 nm emission). All experiments were carried in
quadruplicate.
Distribution of fluorescent edelfosine analog in
S. mansoni
Four couples of adult worms were transferred and maintained in
RPMI-1640 medium supplemented with 20 mM HEPES, 100
IU/mL penicillin, 100 mg/mL streptomycin. Each well of a 24-
well culture plate containing 2 mL of RPMI-1640 culture medium
and two parasitic couples was incubated for 1 h with 10 mM of the
Anti-Schistosomal Activity of Ether Lipid Edelfosine
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fluorescent edelfosine 1-O-[119-(60-ethyl-10,30,50,70-tetramethyl-40,
40-difluoro-40-bora-3a0,4a0-diaza-s-indacen-20-yl)undecyl]-2-O-
methyl-rac-glycero-3-phosphocholine [37,38]. In addition, two
parasitic couples were incubated in RPMI-1640 only (control of
autofluorescence). Parasites were analyzed with a Zeiss
Axioplan 2 fluorescence microscope (Carl Zeiss, Oberkochen,
Germany). All experiments were performed in quadruplicate.
Assessment of apoptosis by TUNEL Assay
The DeadEnd Fluorometric TUNEL System (Promega,
Madison, WI) was used to detect apoptosis. Parasite sections
(4 mm) were deparaffinized in xylene, and rehydrated in graded
ethanol and distilled water. After being rinsed three time with
PBS, the slides were permeabilized with proteinase K (20 mg/mL)
in proteinase K buffer (100 mM Tris-HCl, pH 8.0, 50 mM
EDTA) for 15 min at room temperature. The slides were
incubated with equilibrium buffer [200 mM potassium cacodylate,
25 mM Tris-HCl, pH 6.6, 0.2 mM dithiothreitol (DTT),
0.25 mg/mL bovine serum albumin, 2.5 mM cobalt chloride] at
room temperature for 30 min, followed by assessment of cell
apoptosis with a terminal deoxynucleotidyl transferase dUTP nick
end labeling kit according to the manufacturer’s instructions, and
using fluorescence microscopy (Carl Zeiss). In histological sections,
the apoptotic index, defined as the percentage of apoptotic cells,
was used as a quantitative measure of apoptosis. The apoptotic
index was determined as follows: (number of TUNEL-positive
cells/total number of cells) x 100.
Histopathological analysis
Parasites were fixed in 4% buffered paraformaldehyde and
embedded in paraffin. The tissue sections of schistosomes (4 mm)
were deparaffinized and hydrated in graded ethanol and PBS, and
stained with hematoxylin and eosin (H&E). Histopathological
evaluation was done under microscope analysis. The slides were
viewed using an Olympus BX51 microscope coupled with
Olympus DP Controller software to capture images [39,40].
In vivo study of antischistosomal activity
Six-week-old female CD1 mice (Charles River), weighing 23–
26 g, were kept in the Animal Experimentation Facility. Mice
were randomly allocated into three experimental groups and all
were chemically restrained and percutaneously exposed to 150 S.
mansoni cercariae per animal [32]. Group 1 received the vehicle
solution (water) via oral administration from day 42 to day 52 post-
infection (p.i.) (n = 7); group 2 were orally treated with 500 mg/
kg/day of PZQ on days 47 and 48 p.i. (n = 7); and group 3 were
orally treated with 45 mg/kg/day of edelfosine from day 42 and
52 p.i. (n = 7). Mice were euthanized at week 9 p.i. with a lethal
dose of pentobarbital (60 mg/kg), and then perfused to recover
adult worms from portal and mesenteric veins [31,32]. The
number of parasite eggs per gram (epg) in liver was counted after
digestion with 25 mL 5% KOH (16 h at 37uC with gentle shaking)
[41].
Figure 2. In vitro effects of APLs on the viability of S. mansoni adult worms measured by MTT assay. Couples of adult worms were treated
with edelfosine (EDLF), miltefosine (MILTE), perifosine (PERI) or erucylphosphocholine (ErPC) at the indicated concentrations for 168 h. Data are
means 6 SEM of three separate experiments. Asterisks represent statistical significance with respect to control-live group. (*) P,0.05; (***) P,0.001.
doi:10.1371/journal.pone.0109431.g002
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Statistical analysis
Results were analyzed in GraphPad Prism Version 5 (Graphpad
Software Inc.) and are expressed as mean 6 SEM. Test for
normality was performed by Kolmogorov-Smirnov, and then one-
way ANOVA analysis of variance, followed by Dunnett’s or
Kruskall Wallis comparison test, were performed to determine any
statistical differences between treated groups and untreated
controls. The data were considered significant if P-value was ,
0.05.
Results
In vitro schistosomicidal activity of APLs
First we analyzed the schistosomicidal activity of the four most
clinically relevant APLs, namely edelfosine, perifosine, miltefosine
and erucylphosphocholine, used at the range of 1–80 mM, against
adult worms. By testing parasite viability using the MTT assay
after 168 h incubation, we found that edelfosine was the most
active APL in killing S. mansoni adult worms, being effective at
20 mM, whereas miltefosine was inactive even at the highest
concentration used (80 mM) (Figure 2). Perifosine decreased
parasite viability at 40 mM and erucylphosphocholine at 80 mM
(Figure 2). The differential schistosomicidal activity of the above
APLs was further supported by the microscopic observation of S.
mansoni adult worms incubated as above with the four APLs at a
concentration range of 1–80 mM to examine separation of coupled
pairs, mortality, decrease in motor activity, and tegumental
alterations as shown in Table 1 and Tables S1–S3. Again,
edelfosine was the most potent APL in promoting parasite death
(50% at 10 mM and 100% at 20 mM) in S. mansoni adult forms
after 168 h treatment (Table 1). Incubations with 1 and 5 mM
edelfosine resulted in effects on motor activity and tegumental
alterations (Table 1), indicating that S. mansoni adult forms were
very sensitive to edelfosine treatment. Perifosine also showed
significant schistosomicidal activity, but higher drug concentra-
tions were required to achieve similar effects to those exerted by
edelfosine (Table 1; Tables S1–S3). In contrast, erucylphospho-
choline (erucyl-PC) and miltefosine required very high doses of.
40 mM to elicit some effects on the parasites (Table 1). On the
basis of these morphological observations, erucylphosphocholine
was only able to kill parasites at 80 mM, whereas miltefosine was
unable to promote parasite death even at that concentration
(Table 1), thus further supporting the above MTT data.
Dose- and time-dependent effects of edelfosine on
S. mansoni adult worms
Because edelfosine was the most potent APL against S. mansoni
adults, we further analyzed the effects of this drug on these worms.
A time-course analysis of the effect of different concentrations of
edelfosine showed that this drug could kill S. mansoni adult worms
when incubated at 20 mM for 72 h (Figure 3) and at 30 mM for
48 h incubation (Figure 3). This is of interest as this concentration
range was similar to that found as steady-state concentration of
edelfosine in plasma (10–20 mM) in animal model in vivo assays
[21,22,42]. The induction of structural damage and death in S.
mansoni adult parasites by edelfosine was further supported by
time-lapse videomicroscopy (Video S1), showing an increased
intestinal lumen and oral as well as ventral sucker paralysis. In
addition, membrane permeabilization was detected by incorpora-
tion of propidium iodide (PI) into dead parasites (Figure 4A).
Parasite motility was also observed and measured under an
inverted light microscope, as lack of motility represents the death
of the parasite. We found that low concentrations of edelfosine (5–
10 mM) were enough to promote structural changes in the
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parasite, both in motor activity reduction and in the tegument, as
well as to split the pairs of coupled adult worms into individual
female and male worms (Table 1 and Video S1), the latter being
more affected than the former following incubation with 10 mM
edelfosine.
Effect of edelfosine on the egg production of S. mansoni
adult worms
Schistosome eggs are considered a major cause of liver injury
and illness. About half of the laid eggs lodge in the liver sinusoids,
where they are trapped acting as granulomatogenic triggers,
granuloma formation being strictly dependent on viable mature
eggs [43]. In order to evaluate the action of edelfosine on egg
production by adult worms of S. mansoni, edelfosine was
incubated at different concentrations for 168 h. As shown in
Fig. 4B, edelfosine (5–80 mM) treatment showed a significant
decrease in the number of eggs after 168 h of incubation. The
effect of edelfosine on the separation of the coupled adult worms
could be related to this decrease on egg production.
Figure 3. In vitro effects of edelfosine (EDLF) on the viability of S. mansoni adult worms measured by MTT assay. Couples of adult
worms were treated with EDLF at the indicated concentrations for 24 h, 48 h and 74 h. Data are means 6 SEM of three separate experiments.
Asterisks represent statistical significance with respect to control-live group. (**) P,0.01; (***) P,0.001.
doi:10.1371/journal.pone.0109431.g003
Figure 4. In vitro effects of edelfosine (EDLF) on the viability of S. mansoni adult worms measured by propidium iodide (PI)
permeabilization and in vitro effects of edelfosine on egg production. Couples of adult worms were treated with EDLF at the indicated
concentrations for 24 h (A) or 168 h (B), and then analyzed for membrane permeabilization using PI staining (A) and for the number of laid eggs,
monitored using an inverted microscope (B). RFU, relative fluorescence units. Data are means 6 SEM of three separate experiments. Asterisks
represent statistical significance with respect to control-live group. (**) P,0.01; (***) P,0.001.
doi:10.1371/journal.pone.0109431.g004
Figure 5. Distribution of the fluorescent edelfosine analog in S.
mansoni adult female worms. A) Control of autofluorescence in a
female cultured in RPMI-1640 only. B) Female incubated with the
fluorescent edelfosine analog. Arrows show a slightly increased staining
at the tegument. Scale bar, 0.2 mm.
doi:10.1371/journal.pone.0109431.g005
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Distribution of fluorescent edelfosine analog in pairs of
adult S. mansoni worms
The major interface and physical barrier between the schisto-
some and its external environment is through the tegument,
consisting of a syncytium enclosed by a double outer tegumental
membrane made up of two apposed lipid bilayers, which coats the
worm and is a prime site of intimate host-parasite interaction. It
performs vital functions and is of crucial importance for
modulation of the host response and parasite survival [28]. By
using the fluorescent edelfosine analog 1-O-[119-(60-ethyl-
10,30,50,70-tetramethyl-40,40-difluoro-40-bora-3a0,4a0-diaza-s-inda-
cen-20-yl)undecyl]-2-O-methyl-rac-glycero-3-phosphocholine, which
has been previously used as a reliable analog of edelfosine to analyze
its subcellular localization in single cells [37,38], we found that adult
S. mansoni worms took up the fluorescent analog, showing a rather
diffuse staining in the whole worm, although it appeared to be most
concentrated at the tegument (Figure 5). Thus, these data indicate
that edelfosine is incorporated at the adult worm with a major
tegumental location.
Edelfosine induces apoptosis-like death in S. mansoni
adult worms and changes at the tegument
Induction of apoptotic cell death is one of the main mechanisms
by which edelfosine exerts its antitumor action [20,24,25]. On
these grounds, we analyzed whether edelfosine could promote
apoptosis in S. mansoni adult worms, by using the terminal
deoxynucleotidyl transferase-mediated dUTP nick-end labeling
(TUNEL) technique for detecting DNA damage. Labeling of the
39-OH ends of DNA, generated by DNA fragmentation, through
incorporation of fluorescein-12-dUTP allowed visualization of
apoptotic cells as green fluorescent cells. Worms were permeabi-
lized and stained with 49,6-diamidino-2-phenylindole (DAPI) and
Figure 6. Edelfosine-induced apoptosis-like death as assessed by TUNEL assay. Adult worms were untreated (Control) or treated with
20 mM edelfosine (EDLF) for 12 h, 48 h and 72 h. Worms were analyzed by fluorescence microscopy for propidium iodide (PI) staining and TUNEL
assay, as well as for DAPI staining (nuclei) and light microscopy morphology. Merging of PI and TUNEL panels (Merge) shows the apoptotic nuclei in
yellow. Data shown are representative of four independent experiments. Histograms indicate the percentage of TUNEL-positive cells, as an estimate
of cells undergoing apoptosis. For each experiment, at least 100 cells were analyzed. Data are means 6 SEM of three separate experiments. Asterisks
represent statistical significance with respect to control-live group. (***) P,0.001. Scale bar, 100 mm.
doi:10.1371/journal.pone.0109431.g006
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Figure 7. Morphological changes in S. mansoni adult worms following praziquantel or edelfosine treatments. H&E stained sections of
freshly recovered male parasites that were untreated (Control) or treated with 10 mM praziquantel (PZQ) or 20 mM edelfosine (EDLF) for 2 days.
Tubercle collapse (arrow), damages of the tegument surface, vacuolization of the subtegumental cells (asterisk) and destruction of muscle layers
(arrowhead) were observed after treatment with PZQ or EDLF.
doi:10.1371/journal.pone.0109431.g007
Figure 8. Effect on adult worm and egg burdens after treatment of S. mansoni-infected mice with praziquantel (PZQ) or edelfosine
(EDLF). (A) male and female worm burdens. (B) egg burden in liver. Infected mice were treated with 500 mg/kg (x2) PZQ or 45 mg/kg (x10) EDLF.
Each point represents data from an individual mouse. Horizontal bars indicate average values. (*) P,0.05. (**) P,0.01.
doi:10.1371/journal.pone.0109431.g008
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propidium iodide (PI) to visualize all nuclei from both non-
apoptotic and apoptotic cells in blue and red, while TUNEL-
positive cells were stained yellow in the row of the merged images
and non apoptotic cells as pink fluorescent cells. We found a
potent apoptosis-like response in edelfosine-treated S. mansoni
adult worms, this apoptotic-like response being particularly
abundant in cells close to the tegument (Figure 6). This
edelfosine-induced apoptosis-like response increased with the
incubation time (Figure 6). In addition, edelfosine treatment led
to severe lesions of the tegument and subtegument tissues in both
male and female worms, such as: i) tubercle collapse; ii) exfoliation
and erosion of the tegument surface together with exposure and
vacuolization of the subtegumental cells in the perinuclear
cytoplasm of syncytium and epithelium; iii) extensive destruction
of muscle layers (Figure 7 and Video S1).
In vivo schistosomicidal activity of edelfosine in mice
infected by S. mansoni
Daily oral administration of 15 or 30 mg/kg edelfosine was well
tolerated by CD1 mice, 45 mg/kg being the maximum tolerated
dose, following toxicity analyses, where animals were monitored
for body weight loss or any appreciable side effect, including
changes in strength and general condition. We found that oral
treatment of mice infected with S. mansoni led to a reduction in
the male (46.84 %) and female (29.1 %) worm burdens
(Figure 8A), the decrease in male worm burden being statistically
significant. PZQ treatment led to a practically complete depletion
of adult worms (Figure 8A), so praziquantel treatment was more
potent than that of edelfosine. Interestingly, edelfosine treatment
dramatically decreased the total number of eggs recovered in livers
(54.2% reduction), this inhibition in egg production being
statistically significant as was the corresponding reduction (77%)
exerted by praziquantel (Figure 8B).
Discussion
Our results show the first evidence for the in vitro and in vivo
schistosomicidal activity of the ether phospholipid edelfosine. This
ether lipid is considered as the prototype of APLs, a family of
compounds that act as promising drugs for diverse biomedical
applications, including the treatment of parasitic diseases [19,44].
Two previous reports have shown in vivo [28] and in vitro [45].
schistosomicidal activity of the APL miltefosine. However, here we
found that edelfosine showed a more potent schistosomicidal
activity, and APLs ranked edelfosine. perifosine. erucylpho-
sphocholine. miltefosine for their in vitro activity against S.
mansoni adult worms. Edelfosine shows also in vivo schistosomi-
cidal activity, and although its activity is not as potent as that of
praziquantel, the current drug of choice for schistosomiasis
treatment, our data indicate that oral treatment with edelfosine
decreases significantly the egg burden in liver, a key event in
schistosomiasis. Our present data suggest that edelfosine is
incorporated mainly in the worm tegument, promoting tegumen-
tal alterations, membrane permeabilization, motility impairment,
blockade of male-female pairing and additional structural changes,
which eventually lead to parasite death. In addition, we showed
the induction of apoptosis-like cell death in cells apposed to the
tegument, as visualized by TUNEL assays.
The integrity and function of the surface tegumental membrane
are critical to the survival and proliferation of Schistosoma. The
tegument, a syncytium covered by two lipid bilayers that is a
unique structure to all trematodes [46–49]. In fact the two lipid
bilayer structure pertains only to trematodes that live within blood
vessels [50], plays vital roles like evasion of the immune system,
acquisition of nutrients, excretion of catabolic products, targeted
drug absorption and other physiological processes [47,49,51–54].
Most of the drugs active against schistosomiasis damage the worm
tegument, including praziquantel [55], oxamniquine [56], arte-
mether [57], mefloquine [34,58], atorvastatin alone or in
combination with medroxyprogesterone acetate [59], and
thioxo-imidazoline compounds [60]. Scanning electron microsco-
py studies have recently shown that miltefosine induces severe
tegumental damage in adult schistosomes [28,45,61]. In this
regard, our present data on the tegumental damage elicited by
edelfosine agree with those previously reported with miltefosine
[28,45], thus suggesting that APLs could be promising drugs for
schistosomiasis. Furthermore, miltefosine has been reported to
have in vitro ovicidal, larvicidal as well as lethal activity on adult
worms of S. mansoni and S. haematobium, and displays
molluscicidal activity on their snail hosts [61]. Miltefosine is
approved for use in humans against leishmaniasis [27,62], and
pharmacokinetic as well as different studies on animal models have
shown the relative lack of significant toxicity of edelfosine when
used at pharmacologically relevant doses [21,22,38,42,63]. On
these grounds, APLs might be promising and rather safe drugs for
the treatment of schistosomiasis.
Since the 1970s the treatment of schistosomiasis has relied on a
single drug, praziquantel, [8,64,65], that is considered as the gold
standard and the drug of choice, having been successfully used
over the past 35 years to control schistosomiasis in many countries.
This exclusive dependency on praziquantel is alarming, raising
concerns about the reliance on a single drug to treat over 200
million people that might lead to the potential appearance of
massive resistance to the drug [10,11,16,65–68]. As a result,
identification of alternative schistosomiasis chemotherapies is a
high priority issue.
The results shown here indicate that edelfosine significantly
decreases egg burden in vitro and in vivo. This effect could be due,
at least in part, to the separation of male and female schistosomes
parasites induced by edelfosine, since female schistosomes produce
eggs only when they are in intimate association with a male [69].
Edelfosine kills mainly adult male worms through an apoptosis-like
cell death mechanism. In this regard, it is worth mentioning that
edelfosine is a proapoptotic agent in cancer cells [20,24,25], and it
seems to promote an apoptosis-like process in Leishmania parasites
[26]. The likely involvement of different mechanisms of action for
the schistomicidal activities of praziquantel and edelfosine might
suggest that the combination of these two drugs could promote a
synergistic action and/or minimize the possibility of drug
resistance, as has been proposed for the combined use of
praziquantel and artemisinin derivatives or mefloquine [70,71].
Taking together the results herein reported as well as our previous
studies showing the leishmanicidal activity of edelfosine, it might
be envisaged that this drug could be of special interest in the
treatment of patients that are co-infected with both Leishmania
and Schistosoma parasites [29,30,72–74].
The studies reported here provide for the first time compelling
evidence for schistomicidal activity of edelfosine, which, together
with the low toxicity profile and the anti-inflammatory activity
shown by this APL [21,22,38,63], warrant further studies for the
putative use of edelfosine as a possible treatment against
schistosomiasis.
Supporting Information
Table S1 In vitro effects of edelfosine and perifosine on
56-day-old S. mansoni worms upon 24 h of culture.
(XLSX)
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Table S2 In vitro effects of edelfosine and perifosine on
56-day-old S. mansoni worms upon 48 h of culture.
(XLSX)
Table S3 In vitro effects of edelfosine and perifosine on
56-day-old S. mansoni worms upon 72 h of culture.
(XLSX)
Video S1 In vitro effects following edelfosine treatment
on S. mansoni adult worms. Untreated control group (Live)
shows no alteration in morphology and was able to produce eggs.
Dead worms following heating at 56uC or treatment with 10 mM
praziquantel (PZQ) (positive controls) showed no motility and
became nontranslucent. Worms treated with the indicated
concentrations of edelfosine (EDLF) for 48 h, 72 h and 168 h
showed toxic actions when used $ 10 mM. In the video one arrow
shows severely dilated gut of a female worm and two arrows show
extensive damage on the tegument of a male worm following
treatment with 30 mM of EDLF for 48 h. After the 4:30 min,
another arrow shows extensive peeling in the tegument of a female
worm treated with 10 mM EDLF for 168 h.
(MOV)
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